Spero Therapeutics falls after FDA declines to approve UTI drug

Spero Therapeutics

27/06/2022 21:15

** Shares of Spero Therapeutics Inc  SPRO.O  fall 18% to 77
cents after the bell
    ** SPRO says the U.S. Food and Drug Administration declined
to approve co's oral antibiotic drug, tebipenem HBr, for the
treatment of patients with complicated urinary tract infections
 urn:newsml:reuters.com:*:nL4N2YE2W4
    ** Up to last close, stock down over 94% YTD

 (Reporting by Chavi Mehta in Bengaluru)
 ((Chavi.Mehta@thomsonreuters.com;))